TTKHLTCARE2023-04-012023-06-30 TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member TTKHLTCARE2023-06-30 TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneReportableSegmentRevenue01Member TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneReportableSegmentRevenue02Member TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneReportableSegmentRevenue03Member TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneReportableSegmentRevenue04Member TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneReportableSegmentRevenue05Member TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneReportableSegmentRevenue06Member TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneReportableSegmentResults01Member TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneReportableSegmentResults02Member TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneReportableSegmentResults03Member TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneReportableSegmentResults04Member TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneReportableSegmentResults05Member TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneReportableSegmentResults06Member TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneReportableSegmentAssets01Member TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneReportableSegmentAssets02Member TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneReportableSegmentAssets03Member TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneReportableSegmentAssets04Member TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneReportableSegmentAssets05Member TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneReportableSegmentAssets06Member TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneReportableSegmentLiabilities01Member TTKHLTCARE2023-06-30in-bse-fin:OneReportableSegmentLiabilities01Member TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneReportableSegmentLiabilities02Member TTKHLTCARE2023-06-30in-bse-fin:OneReportableSegmentLiabilities02Member TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneReportableSegmentLiabilities03Member TTKHLTCARE2023-06-30in-bse-fin:OneReportableSegmentLiabilities03Member TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneReportableSegmentLiabilities04Member TTKHLTCARE2023-06-30in-bse-fin:OneReportableSegmentLiabilities04Member TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneReportableSegmentLiabilities05Member TTKHLTCARE2023-06-30in-bse-fin:OneReportableSegmentLiabilities05Member TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneReportableSegmentLiabilities06Member TTKHLTCARE2023-06-30in-bse-fin:OneReportableSegmentLiabilities06Member TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member TTKHLTCARE2023-04-012023-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 507747 TTKHLTCARE NOTLISTED TTK Healthcare Limited Equity 2023-04-01 2024-03-31 2023-08-01 2023-07-14 INR Lakhs First quarter 12:00:00 13:00:00 2023-08-01 2023-08-01 Not applicable Multi segment 2023-04-01 2023-06-30 Unaudited Standalone 2021235000.00 146134000.00 2167369000.00 452301000.00 438520000.00 -40138000.00 344413000.00 8599000.00 31558000.00 725730000.00 1960983000.00 206386000.00 0.00 206386000.00 53000000.00 -3305000.00 49695000.00 0.00 156691000.00 0.00 0.00 0.00 0.00 156691000.00 9216000.00 165907000.00 0.00 0.00 141303000.00 10 11.09 11.09 0.00 0.00 11.09 11.09 (1)The above financial results for the Q1 ended 30.06.23 in respect of TTK Healthcare Limited have been reviewed by the AC at its meeting held on 31.07.23 & approved by the BOD of the Co. at its meeting held on 01.08.23 at the RO of the Co. also, with the provision of VC(2)The Statutory Auditors of the Co. have carried out Limited Review of the above Unaudited Financial Results in terms of R.33 of the SEBI (LODR) R., 2015.(3)(a)Profit from Discontinued Operations (pertaining to previous year):(i)Gain on sale of undertaking:During the Q1 of FY22-23, the necessary formalities for transfer of the Human Pharma Division (HPD) of the Co. were completed & the HPD stood transferred as a going concern on slump sale basis, for a consideration of Rs.80500 lakhs (final consideration of Rs.80281.54 lakhs after working capital & other customary adjustments) to BSV Pharma P. L. w.e.f 09.05.22.The consideration for the transfer was 74% cash (Rs.59442.51 lakhs) & 26% in the form of Eq of the buying entity. The terms of transfer also provided for purchase of the aforesaid 26% Equity Shares held by the Co. in BSV, by Bharat Serums & Vaccines Limited or its nominees, after they obtain necessary regulatory clearances at the issue price.During the Q3 of FY22-23, the above shares were transferred to M/s Bharat Serums & Vaccines L. & the consid. of Rs.20839.03 lakhs for the shares was received by the Co.The gain on sale of this Undertaking amounted to Rs.76,429.45 lakhs (after providing for Rs.1,500 lakhs towards contingencies of which Co. had incurred expenses amounting to Rs.266.58 lakhs till 31.03.23).(ii)Profit from HPD Operations:The total income of HPD up to the date of sale (i.e.) 09.05.22 was Rs.2240.57 lakhs (including reversal of provision made towards damaged / expired stock returns in the earlier years amounting to Rs.1132.29 lakhs which was no longer required) & its total expenses were Rs.1026.10 lakhs resulting in a net profit of Rs.1214.47 lakhs.(b)Tax expense of Discontinued Operations:The tax expense on sale of HPD was Rs.17835.48 lakhs (i.e. Long Term Capital Gain tax expense on the above transfer amounting to Rs.17769.26 lakhs & Deferred Tax expenses of Rs.66.22 lakhs).The tax expense on the profit for the year ended 31.03.23 from the operations of HPD was Rs.303.94 lakhs.(4)Implementation of the Code of Social Security 2020, which was likely to impact the contributions by the Co. towards Provident Fund, Gratuity & other related areas has been deferred by the Government beyond 01.04.21. However, the Co. based on the initial assessment made a provision for Rs.350 lakhs in the Q4 of FY20-21 & proposes to take further appropriate action after the Rules are made applicable.(5)The Co.'s Promoters made an Initial Public Announcement on 05.04.23 in accordance with R. 8 of the SEBI (Delisting of Equity Shares) Regulations, 2021, to acquire all Equity Shares aggregating to 3594493 Eq. Sh. of Rs.10/- each that are held by the Public Shareholders of the Co., either individually / collectively, or together with other members of the Promoter Group, as the case may be; & consequently, voluntarily delist the Eq. Sh. of the Co. from the Stock Exchanges where the Equity Shares are presently listed (i.e.) BSE & NSE. However, as the stipulated threshold limit of 90% of the PSC of the Co. as per the Delisting Regulations was not met through the offer from the Public Shareholders, the delisting proposal was not successful.(6)The figures for the Quarter ended 31.03.23 are the balancing figures between the Audited Figures in respect of the full FY & the published year to date figures upto the end of the Q3 of the relevant financial year which were subjected to Limited Review.(7)The previous period's/year's figures have been regrouped & reclassified, wherever necessary to conform to the current period's/year's presentation.(8)The full financial results for the Q1 ended 30.06.23 are available on the website of BSE, NSE & of the Co. Other Expenses 725730000.00 Animal Welfare 272378000.00 Consumer Products 711766000.00 Foods 299013000.00 Medical Devices 222110000.00 Others 1274000.00 Protective Devices 514694000.00 2021235000.00 2021235000.00 Animal Welfare 12921000.00 Consumer Products 49846000.00 Foods 399000.00 Medical Devices 58009000.00 Others 992000.00 Protective Devices 30259000.00 152426000.00 8599000.00 -62559000.00 Notes: 1.Segments have been identified in line with the Indian Accounting Standard on Segment Reporting (Ind AS 108) based on review of performance by the Top Management. 2.Details of products included in each of the Segments are as below: Animal Welfare (earlier included in Pharmaceuticals Segment) comprise products for Veterinary use. Consumer Products comprise marketing and distribution of Woodward's Gripewater, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Fresheners, etc. Medical Devices include Artificial Heart Valves, Orthopaedic Implants, etc. Protective Devices comprise manufacturing and marketing of Male Contraceptives and other allied products. Foods comprise manufacturing and marketing of Food Products. Others include Printing and Publishing of Maps and Atlases. Human Pharma (earlier included in Pharmaceuticals Segment) comprise products for Human use 3.(a)Segment Results of Human Pharma Division include gain on sale of the Division amounting to Rs.76,429.45 lakhs. (b) Unallocated Segment Assets include consideration on sale of Human Pharma Division received in the form of cash and equity. 4.The segment wise revenue, results, assets and liabilities figures relate to respective amounts directly identifiable to each of the segments. The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment. 5.The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation. 206386000.00 Animal Welfare 416646000.00 Consumer Products 491958000.00 Foods 778375000.00 Medical Devices 707953000.00 Others 24270000.00 Protective Devices 1201597000.00 3620799000.00 Animal Welfare 360777000.00 Consumer Products 718474000.00 Foods 150553000.00 Medical Devices 236989000.00 Others 13372000.00 Protective Devices 438533000.00 1918698000.00 419419000.00 2338117000.00 Items that will not be reclassified subsequently to profit or loss 9818000.00 9818000.00 602000.00 Items that will be reclassified subsequently to profit or loss 0.00 0.00 0.00